PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announces the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual property back to PacBio.
Read the full article: PacBio Completes Sale of Short-Read Sequencing Assets //
Source: https://www.globenewswire.com/news-release/2026/02/02/3230350/16261/en/PacBio-Completes-Sale-of-Short-Read-Sequencing-Assets.html